Delisting risk
Oncolytics Biotech
Develops pelareorep, a double-stranded RNA immunotherapy for gastrointestinal tumors.
$0.8526
After-hours close−0.01 (−0.79%)
At close$0.8594(+1.11%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 3.93%3.94M sharesInsiders 2.36%2.37M sharesOther 93.71%94.05M shares
Shares outstanding 100.36M · Float —
Institutions13F, as of Jun 30, 2026
77 holders · 3.94M shares · 29 new positions · 42 increased · 9 reduced · 9 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Marshall Wace, LLP | 745.4K | 0.74% | −114.5K | Aug 13, 2026 |
| XTX Topco Ltd | 260.9K | 0.26% | +260.9Knew | Aug 14, 2026 |
| Seeds Investor LLC | 258.3K | 0.26% | +258.3Knew | Aug 12, 2026 |
| International Assets Investment Management, LLC | 201.3K | 0.20% | +201.3Knew | Jul 22, 2026 |
| Connective Capital Management, LLC | 185.7K | 0.19% | +185.7Knew | Aug 13, 2026 |
| Goldman Sachs Group Inc | 169.9K | 0.17% | +169.9Knew | Aug 14, 2026 |
| Tocqueville Asset Management L.P. | 147.0K | 0.15% | +147.0Knew | Aug 10, 2026 |
| Everhart Financial Group, Inc. | 140.9K | 0.14% | +140.9Knew | Jul 9, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Anson Funds Management LP | 7.00% | 7.65M | 13G | Nov 14, 2025 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Bernd R. Seizinger | director | 567.0K | 0.56% | Feb 13, 2026 |
| Wayne Pisano | director | 492.4K | 0.49% | Feb 13, 2026 |
| Kirk Look | officer: Chief Financial Officer | 287.5K | 0.29% | Feb 13, 2026 |
| Thomas Charles Heineman | officer: Chief Medical Officer | 282.8K | 0.28% | Feb 13, 2026 |
| Angela Holtham | director | 183.6K | 0.18% | Jan 2, 2026 |
| Allison Hagerman | officer: VP, Product Development | 115.1K | 0.11% | Feb 13, 2026 |
| Jared Kelly | director, officer: Chief Executive Officer | 114.1K | 0.11% | Mar 13, 2026 |
| Deborah Margaret Brown | director | 109.9K | 0.11% | Feb 13, 2026 |
| Patricia S. Andrews | director | 78.1K | 0.08% | Feb 13, 2026 |
| Andrew Aromando | officer: Chief Business Officer | 55.1K | 0.05% | Feb 13, 2026 |
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Mar 12, 2026 | Jared Kellydirector, officer: Chief Executive Officer | Purchase | 5,050 | $0.9600 | 114,050 |
| Mar 11, 2026 | James T. Parsonsdirector | Purchase | 10,000 | $1.03 | 41,849 |
| Feb 12, 2026 | Patricia S. Andrewsdirector | Purchase | 35,400 | $0.8557 | 78,128 |
| Feb 11, 2026 | Andrew Aromandoofficer: Chief Business Officer | Purchase | 29,600 | $0.8587 | 55,100 |
| Feb 11, 2026 | Bernd R. Seizingerdirector | Purchase | 60,000 | $0.8265 | 526,991 |
| Feb 12, 2026 | Bernd R. Seizingerdirector | Purchase | 40,000 | $0.8466 | 566,991 |
| Feb 12, 2026 | Allison Hagermanofficer: VP, Product Development | Purchase | 10,000 | $0.8298 | 115,059 |
| Feb 12, 2026 | Deborah Margaret Browndirector | Purchase | 25,000 | $0.8496 | 109,851 |
| Feb 12, 2026 | Thomas Charles Heinemanofficer: Chief Medical Officer | Purchase | 12,132 | $0.8270 | 282,818 |
| Feb 12, 2026 | Wayne Pisanodirector | Purchase | 30,000 | $0.8446 | 492,414 |
CongressHouse and Senate disclosures
Not reported.